"Foscarnet" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
| Descriptor ID |
D017245
|
| MeSH Number(s) |
D02.241.081.018.677.250 D02.705.429.875.500
|
| Concept/Terms |
Foscarnet Sodium- Foscarnet Sodium
- Sodium, Foscarnet
- Foscarnet Trisodium Salt
- Trisodium Salt, Foscarnet
- Foscarnet Sodium Hexahydrate
- Hexahydrate, Foscarnet Sodium
- Sodium Hexahydrate, Foscarnet
- Trisodium Phosphonoformate
- Phosphonoformate, Trisodium
|
Below are MeSH descriptors whose meaning is more general than "Foscarnet".
Below are MeSH descriptors whose meaning is more specific than "Foscarnet".
This graph shows the total number of publications written about "Foscarnet" by people in this website by year, and whether "Foscarnet" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 4 | 2 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Foscarnet" by people in Profiles.
-
Cytomegalovirus in Pediatric Hematopoietic Stem Cell Transplantation: A Case-Based Panel Discussion of Current Challenges. J Pediatric Infect Dis Soc. 2018 Dec 26; 7(suppl_2):S72-S74.
-
New Developments in the Management of Cytomegalovirus Infection After Transplantation. Drugs. 2018 Jul; 78(11):1085-1103.
-
Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: A single-center study. Transpl Infect Dis. 2018 Apr; 20(2):e12852.
-
Ganciclovir and foscarnet dual-therapy for cytomegalovirus encephalitis: A case report and review of the literature. J Neurol Sci. 2018 05 15; 388:28-36.
-
Cytomegaloviraemia clearance with foscarnet during renal replacement therapy. J Antimicrob Chemother. 2018 02 01; 73(2):548-549.
-
Antiviral combination therapy for cytomegalovirus infection in high-risk infants. Antivir Ther. 2018; 23(6):505-511.
-
Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case report. Medicine (Baltimore). 2017 Feb; 96(6):e5621.
-
Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature. Transpl Infect Dis. 2013 Dec; 15(6):E243-9.
-
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet. Bioorg Med Chem Lett. 2004 Dec 06; 14(23):5763-7.
-
Antiviral activity of ganciclovir elaidic acid ester against herpesviruses. Antiviral Res. 2000 Mar; 45(3):157-67.